Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn's ileal disease

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2005, Pages 557-564

  Laghi, L ^a   Costa, S ^b   Saibeni, S ^b   Bianchi, P ^a   Omodei, P ^a   Carrara, A ^b,c   Spina, L ^b   Contessini Avesani, E ^b,c   Vecchi, M ^b,c   De Franchis, R ^b,c   Malesci, A ^a,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15;

ADULT; ANAMNESIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE DETECTION; HUMAN; ILEUM RESECTION; ITALY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ADULT; CROHN DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ILEAL DISEASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; POLYMERASE CHAIN REACTION; RISK FACTORS; SMOKING;

EID: 25444505048     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02629.x     Document Type: Article

References (24)

1. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
2. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
3. Hampe J, Cuthbert A, Crouche PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British population. Lancet 2001; 357: 1925-8.
4. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122: 854-66.
5. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122: 867-74.
6. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123: 679-88.
7. Lesage S, Zouali H, Cezard JP, et al. CARD 15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845-57.
8. Murillo L, Crusius B, van Bodegraven AA, Alizadeh BZ, Pena AS. CARD15 gene and the classification of Crohn's disease. Immunogenetics 2002; 54: 59-61.
9. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359: 1661-5.
10. Helio T, Halme L, Lappalainen L, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003; 52: 558-562.
11. Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004; 126: 1533-49.
12. Chamaillard M, Philpott D. Girardin SE, et al. Gene-environmental interaction modulated by allelic heterogeneity in inflammatory bowel disease. Proc Natl Acad Sci USA 2003; 100: 3455-60.
13. Bonen D, Ogura Y, Nicolae DL, et al. Crohn's disease-associated NOD2 variants share a signalling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003; 124: 140-6.
14. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-54.
15. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of smoking on the long-term course of Crohn's disease. Gastroenterology 1996; 110: 424-31.
16. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52: 552-7.
17. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behavior of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782.
18. Giachino D, Van Duist MM, Regazzoni S, et al. Analysis of the CARD15 variant R702W, G908R and L1007fs in Italian IBD patients. Eur J Hum Gen 2004; 12: 2016-212.
19. Vavassori P, Borgiani P, D'Apice MR, et al. 3020insC mutation within the NOD2 gene in Crohn's disease: frequency and association with clinical pattern in an Italian population. Dig Liver Dis 2002; 34: 153.
20. Vermiere S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71: 74-83.
21. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis 2003; 9: 281-9.
22. Buning C, Genschel J, Buhner S, et al. Mutations in the NOD2/ CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004; 19: 1073-8.
23. Smith BRK, Arnott IDR, Drummond HE, Nimmo ER, Satsangi J. Disease location, anti-saccharomyces cerevisiae antibody, NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis 2004; 10: 521-8.
24. Takada Y, Khuri FR, Aggarwal BB. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004; 279: 26287-99.